Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.69 |
| ▸ | TK1 | P04183 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19132672 | 1.00 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL12670320 | 1.00 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL16359947 | 1.00 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL25756080 | 1.00 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL523267 | 1.00 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL10431982 | 1.00 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL8996152 | 0.91 | RNASE1 (0.70) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL22992460 | 0.91 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL4286458 | 0.91 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL2056647 | 0.91 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3165606-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-1730309-B1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | IONIS PHARMACEUTICALS INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9303055-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2700720-A2 | Compositions and methods for optimizing cleavage of RNA by RNASE H | Isis Pharmaceuticals, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130261026-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2002072791-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | disclosed |
| US-6191266-B1 | MODIFIED TO COMPRISE SUBSTITUTIONS AT POSITIONS C1', C3', C4' OR C5' OF THE SUGAR MOIETY OF THE NUCLEOSIDE, INCLUDING AN OPTIONAL 3' PHOSPHOROAMIDITE GROUP; USE IN MAKING NUCLEASE RESISTANT OLIGONUCLEOTIDES FOR ANTISENSE THERAPY | ICN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0789706-A4 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5712378-A | SUGAR MOLECULE IS SUBSTITUTED WITH HYDROCARBON OR SUBSTITUTED HYDROCARBON GROUPS, ANTISENSE AGENTS | ICN PHARMACEUTICALS (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0789706-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014329-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
| EP-0460045-A1 | NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE LONDON (GB) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990010012-A1 | NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE LONDON (GB) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | RNASE1 116/4885TK1 518/4885LMNA 1098/4885 |
| US-20130261026-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | PCNA, LIG4, DCLRE1A | RNASE1 491/4885TK1 282/4885LMNA 1096/4885 |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | HCCS, HDGF, HMBS | RNASE1 265/4885TK1 65/4885LMNA 1253/4885 |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | OR10J3, RPS8, NSUN2 | RNASE1 2182/4885TK1 2907/4885LMNA 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.